Literature DB >> 22867874

Developing strategies for HIV-1 eradication.

Christine M Durand1, Joel N Blankson, Robert F Siliciano.   

Abstract

Highly active antiretroviral therapy (HAART) suppresses HIV-1 replication, transforming the outlook for infected patients. However, reservoirs of replication-competent forms of the virus persist during HAART, and when treatment is stopped, high rates of HIV-1 replication return. Recent insights into HIV-1 latency, as well as a report that HIV-1 infection was eradicated in one individual, have renewed interest in finding a cure for HIV-1 infection. Strategies for HIV-1 eradication include gene therapy and hematopoietic stem cell transplantation, stimulating host immunity to control HIV-1 replication, and targeting latent HIV-1 in resting memory CD4(+) T cells. Future efforts should aim to provide better understanding of how to reconstitute the CD4(+) T cell compartment with genetically engineered cells, exert immune control over HIV-1 replication, and identify and eliminate all viral reservoirs.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22867874      PMCID: PMC3963166          DOI: 10.1016/j.it.2012.07.001

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  107 in total

1.  Attacking latent HIV provirus: from mechanism to therapeutic strategies.

Authors:  Nancy M Archin; David M Margolis
Journal:  Curr Opin HIV AIDS       Date:  2006-03       Impact factor: 4.283

2.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

3.  HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication.

Authors:  Olivier Lambotte; Faroudy Boufassa; Yoann Madec; Ahn Nguyen; Cécile Goujard; Laurence Meyer; Christine Rouzioux; Alain Venet; Jean-François Delfraissy
Journal:  Clin Infect Dis       Date:  2005-08-30       Impact factor: 9.079

Review 4.  Histone deacetylase inhibitors and HIV latency.

Authors:  David M Margolis
Journal:  Curr Opin HIV AIDS       Date:  2011-01       Impact factor: 4.283

Review 5.  A simian immunodeficiency virus macaque model of highly active antiretroviral treatment: viral latency in the periphery and the central nervous system.

Authors:  Janice E Clements; Lucio Gama; David R Graham; Joseph L Mankowski; M C Zink
Journal:  Curr Opin HIV AIDS       Date:  2011-01       Impact factor: 4.283

6.  Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.

Authors:  Sifei Xing; Cynthia K Bullen; Neeta S Shroff; Liang Shan; Hung-Chih Yang; Jordyn L Manucci; Shridhar Bhat; Hao Zhang; Joseph B Margolick; Thomas C Quinn; David M Margolis; Janet D Siliciano; Robert F Siliciano
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

7.  Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established?

Authors:  Cécile Goujard; Marie-Laure Chaix; Olivier Lambotte; Christiane Deveau; Martine Sinet; Julien Guergnon; Valérie Courgnaud; Christine Rouzioux; Jean-François Delfraissy; Alain Venet; Laurence Meyer
Journal:  Clin Infect Dis       Date:  2009-09-15       Impact factor: 9.079

8.  Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.

Authors:  M Dean; M Carrington; C Winkler; G A Huttley; M W Smith; R Allikmets; J J Goedert; S P Buchbinder; E Vittinghoff; E Gomperts; S Donfield; D Vlahov; R Kaslow; A Saah; C Rinaldo; R Detels; S J O'Brien
Journal:  Science       Date:  1996-09-27       Impact factor: 47.728

9.  Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.

Authors:  Hung-Chih Yang; Sifei Xing; Liang Shan; Karen O'Connell; Jason Dinoso; Anding Shen; Yan Zhou; Cynthia K Shrum; Yefei Han; Jun O Liu; Hao Zhang; Joseph B Margolick; Robert F Siliciano
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

10.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

View more
  63 in total

1.  Hematopoietic cell transplantation and HIV cure: where we are and what next?

Authors:  Shimian Zou; Simone Glynn; Daniel Kuritzkes; Monica Shah; Nakela Cook; Nancy Berliner
Journal:  Blood       Date:  2013-09-05       Impact factor: 22.113

2.  An HIV-1 replication pathway utilizing reverse transcription products that fail to integrate.

Authors:  Benjamin Trinité; Eric C Ohlson; Igor Voznesensky; Shashank P Rana; Chi N Chan; Saurabh Mahajan; Jason Alster; Sean A Burke; Dominik Wodarz; David N Levy
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

Review 3.  HIV-1 transcription and latency: an update.

Authors:  Carine Van Lint; Sophie Bouchat; Alessandro Marcello
Journal:  Retrovirology       Date:  2013-06-26       Impact factor: 4.602

4.  Position effects influence HIV latency reversal.

Authors:  Heng-Chang Chen; Javier P Martinez; Eduard Zorita; Andreas Meyerhans; Guillaume J Filion
Journal:  Nat Struct Mol Biol       Date:  2016-11-21       Impact factor: 15.369

5.  Combining Cell and Gene Therapy in an Effort to Eradicate HIV.

Authors:  Thor A Wagner
Journal:  AIDS Patient Care STDS       Date:  2016-12       Impact factor: 5.078

6.  Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection.

Authors:  Louise Leyre; Eugène Kroon; Claire Vandergeeten; Carlo Sacdalan; Donn J Colby; Supranee Buranapraditkun; Alexandra Schuetz; Nitiya Chomchey; Mark de Souza; Wendy Bakeman; Rémi Fromentin; Suteeraporn Pinyakorn; Siriwat Akapirat; Rapee Trichavaroj; Suthat Chottanapund; Sopark Manasnayakorn; Rungsun Rerknimitr; Phandee Wattanaboonyoungcharoen; Jerome H Kim; Sodsai Tovanabutra; Timothy W Schacker; Robert O'Connell; Victor G Valcour; Praphan Phanuphak; Merlin L Robb; Nelson Michael; Lydie Trautmann; Nittaya Phanuphak; Jintanat Ananworanich; Nicolas Chomont
Journal:  Sci Transl Med       Date:  2020-03-04       Impact factor: 17.956

7.  HIV and Stem Cell Transplantation.

Authors:  Ignacio A Echenique; George E Nelson; Valentina Stosor; Christine M Durand
Journal:  Curr Infect Dis Rep       Date:  2014-09       Impact factor: 3.725

8.  Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1.

Authors:  Alison L Hill; Daniel I S Rosenbloom; Feng Fu; Martin A Nowak; Robert F Siliciano
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-05       Impact factor: 11.205

9.  HIV Subtype and Nef-Mediated Immune Evasion Function Correlate with Viral Reservoir Size in Early-Treated Individuals.

Authors:  Fredrick H Omondi; Sandali Chandrarathna; Shariq Mujib; Chanson J Brumme; Steven W Jin; Hanwei Sudderuddin; Rachel L Miller; Asa Rahimi; Oliver Laeyendecker; Phil Bonner; Feng Yun Yue; Erika Benko; Colin M Kovacs; Mark A Brockman; Mario Ostrowski; Zabrina L Brumme
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

10.  Enhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kinetics.

Authors:  Thomas W North; Andradi Villalobos; Selwyn J Hurwitz; Jesse D Deere; Joanne Higgins; Payel Chatterjee; Sijia Tao; Robert C Kauffman; Paul A Luciw; James J Kohler; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.